Knoxprey - instructions for use, doses, side effects, contraindications

Excipients: levomenthol 0.25 mg, camphor racemic 0.15 mg, eucalyptol (cineole) 0.075 mg, benzalkonium chloride 0.2 mg, sodium dihydrogen phosphate monohydrate 2 mg, disodium edetate (trilon B) 0.1 mg, propylene glycol 100 mg, 0, 1 M solution of sodium hydroxide or hydrochloric acid to pH 4.5, water purified - a sufficient amount to 1 ml.

Description:Colorless or slightly yellowish, clear liquid with a specific odor.

Pharmacotherapeutic group:anticonvulsant - alpha-adrenomimetic

ATX: & nbsp

S.01.G.A.04 Oxymetazoline

Pharmacodynamics:

Knoxprey - α-adrenomimetic, an imidazoline derivative, refers to a vasoconstrictor for topical use. If it gets into the nasal cavity, the drug narrows the arterioles of the mucous membrane of the nasal cavity, thereby reducing edema, hyperemia, exudation, nasal breathing is restored, and discharge from the nose decreases. Knoxprey also reduces the swelling of the mucous membrane around the opening of the Eustachian tube, improving drainage with eustachitis and otitis media. Essential oils that make up the drug, help to eliminate irritation of the nasal mucosa, protect it from excessive drying.

Pharmacokinetics:Local narrowing of the vessels of the nasal mucosa and paranasal sinuses occurs in 5-10 minutes after injecting Knoxprey into the nasal cavity and lasts up to 10-12 hours.

Indications:

Acute rhinitis of allergic or infectious-inflammatory etiology, sinusitis, nasal congestion and obstructed nasal breathing for colds, eustachitis, otitis media. To facilitate the conduct of rhinoscopy and other manipulations in the nasal cavity.

Contraindications:

Hypersensitivity to the components of the drug; atrophic rhinitis; pregnancy and lactation; children's age till 6 years.

Carefully:

In chronic heart failure, arrhythmia, severe atherosclerosis, arterial hypertension, thyrotoxicosis, diabetes mellitus, chronic renal failure, closed-angle glaucoma, prostatic hyperplasia with clinical symptoms; simultaneous administration of monoamine oxidase inhibitors, tricyclic antidepressants.

To prevent the spread of infection, do not use one bottle to several people. Avoid prolonged use and overdose of the drug.Long-term use of decongestants can lead to a decrease in their effectiveness. Abuse of these drugs can cause atrophy of the mucous membrane of the nasal cavity and reactive hyperemia with drug rhinitis.

Pregnancy and lactation:

During pregnancy and breastfeeding the drug is used in case of emergency, when the expected benefit for the mother exceeds the potential risk to the fetus or baby.

Dosing and Administration:

The tip of the nozzle of the vial is injected into each nasal passage and pressed sharply once on the vial. During the injection, air is drawn in by the nose. Do not bend back the head and flip the bottle when injecting Knoxprey.

Children aged 6 to 12 years are injected into each nasal passage 2 times a day, children over 12 years and adults - 1-2 injections in each nasal passage 2 times a day. The duration of application should not exceed 7 days.

Side effects:Sometimes - a burning sensation or dryness of the nasal membranes, sneezing. In rare cases, reactive hyperemia. Multiple overdose with local nasal application leads to such systemic sympathomimetic effects,as a tachycardia, insomnia, bAnxiety, increased blood pressure, headache, nausea. It is extremely rare when using Knoxprey, it is possible to develop severe hypersensitivity reactions, including Quincke's edema.

In case of side effects, the drug should be discontinued and consult a doctor.

Overdose:

If there is a significant overdose or accidental ingestion, symptoms may include: miosis, nausea, vomiting, cyanosis, hyperthermia, tachycardia, arrhythmia, vascular insufficiency, arterial hypertension, respiratory distress, pulmonary edema, cardiac arrest, mental disorders. It is extremely rare - oppression of the central nervous system with the possible development of coma. When the drug is overdosed, the stomach is washed and symptomatic therapy is performed.

Interaction:

Knoxprey should not be used concurrently with other local vasoconstrictor and intranasal administration agents, as well as with tricyclic antidepressants and monoamine oxidase inhibitors.

Effect on the ability to drive transp. cf. and fur:

In the recommended doses, the drug does not affect the rate of psychomotor reactions.

Form release / dosage:Spray nasal, 0,05%.

Packaging:

To 20 ml in polymeric bottles with stoppers-sprayers and caps with the control of the first opening.

The bottle, along with the instruction for medical use, is placed in a pack of cardboard.

Storage conditions:

Store at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use the product after the expiration date printed on the package.

Terms of leave from pharmacies:Without recipe

Registration number:LS-001064

Date of registration:24.08.2010

The owner of the registration certificate:SPERKO UKRAINE, JV SPERKO UKRAINE, JV Ukraine

Manufacturer: & nbsp

SPERKO UKRAINE JV Ukraine

Representation: & nbspFC GRAND CAPITAL LLCFC GRAND CAPITAL LLCRussia

Information update date: & nbsp11.08.2015

Illustrated instructions

Instructions

Knoxprey (Noksprey)